MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia
SAN DIEGO — Measurable residual disease (MRD) after induction therapy can guide the use of allogeneic transplant in patients with NPM1-mutated acute myeloid leukemia (AML) in first remission, regardless of whether FLT3 internal tandem duplication (ITD) mutations are present as well, according to an analysis of two randomized trials. Of more than 700 patients in […]
Intensive Pretransplant Consolidation in Older AML Fails to Improve Results
HOUSTON — Intensive consolidation treatment before allogeneic stem-cell transplant did not improve outcomes in older patients with acute myeloid leukemia (AML), a retrospective comparison showed. Relapse-free survival (RFS) at 2 years was virtually identical for patients who received intensive consolidation therapy (51%) and those who did not (50%). The intensive-therapy group had a trend toward […]
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]